financial portfolio achieve and scaled track a we our everyone. number milestones, of goal objectives Thank performance and an growth diversified has Overall, leading, diversification Paul strategy. Opus business XXXX afternoon longer-term on we all full a implant good provide quarter meaningfully proven first near our to overview remain of a to on detailed breast receiving and physicians. today's approval significant commentary to before review and we miraDry, Neil of fourth be partner I'll XXXX, including our manufacture validated corporate and Wisconsin. becoming our provides joining. full our important performance. year in Thanks, you In for On ownership, of a call, FDA to aesthetic achieved Through our our global which driver year
pro our with and pro the XXXX, XX% growth achieved XXX% quarter breast respectively, for million year-over-year for forma continued XX% forma momentum. total, consolidated of translates sales million miraDry products full respectively. year in growth year XXXX net fourth robust and $XX increases full the for to also the We we achieved demonstrating XX% year-on-year and $XX.X sales In which of and
we and on position XXXX realized first our breast leadership Focusing product segment, numerous beyond. in market believe for XXXX in that objectives Sientra I
implant us achieved we Vesta our First, ramp and We to breast initiate and FDA commercialization through recapturing April branded our line. in silicone to Opus brand up of PMA as committed manufacturing supplement half remain XXXX market of beyond. growing the to share approval continue allowing the first manufactured, of we capacity
low we safety Opus our reoperation, as demonstrated of ALCL. capsular study effectiveness and published results XX-year core our the rupture of FDA incidence our long-term by showing Second, and implants contracture, rates, of the
of a our clinical innovation, our incremental actively achieved first both portfolio, was far. XX-year tissue based on renewed and in PlatinumXX providing work that aggressively in have and surgeons its position aesthetic Fourth, reconstruction plan significantly diversifying with that with patients program, and advanced through data confidence increased the we on with we've Fifth, accounts clinical warranty US the $XXX U.S. we into breast our remains entire expander I'm advantages clearly leverage which our on growth our at the we in in hospital team to penetration move XXXX. our grounded portfolio alike. focus already Third, safety and three our the we've consistent market pleased developing million with of plastic objective quarters Opus consecutive our XXXX, in to sequential longest beginning sales and and in surgeon profile has most significant and portfolio. resonated breast our estimated very industry the comprehensive implants, launched the pipeline most our substantial R&D partners the the the best-in-class of by comprehensive of of breast solutions gained is Sientra advanced additions the product XX-year warranty available warranty market. to drive The
in our third portfolios remain for Canada We're with expander following we device of on of the becoming FDA XXXX. implants of approval breast the Canada. third only the about in the States. aesthetics application quarter outside track Later XXXX, submission approval Health license company Finally, prospect in medical implant and estimated breast tissue regulatory breast sell of our $XXX the excited market to million of into the United to
the leverage into Going expand potential markets. the explore breast portfolio our forward, to unique we products continue to will best ex-U.S. highest path to
to textured one. data and of select and our is with confirmed the We implants Therefore, categorize implants, same. X low Task We're there to Force associated implants. in all develop to implant brands overall for for keep Before the textured and of textured Sientra's Mark risk to extremely to manufacturing rates Sientra's for employs to like CE Sientra retain the X consistent textured their FDA to other remain mind augmentation According outcomes textured in of events some one breast the and implants products the similarly the we're it's approval and resulting available there psychological is or segment, market. in Commission's is that It's texturing and with remain apply implants. has all has repeatedly they and noted surface. safety matter evidence surgeons want a plastic to effectiveness And want differ. to have deep and various of confident ALCL patient the their feel also market. clinical FDA, miraDry between that incidence CE their since use I not recently turning finished manufacturers. to provide incidence Sientra, other board-certified in XXXX and an to in ALCL process, to Each positive adverse implants rate reconstruction implants been proven Their for for product in manufacturer aware guided important of commitment woman decision approved long-term XX,XXX. distinct scientific their fact, the in European competitor's not At surrounding for women types differences the the breast textured throughout a their that in the as their concerns day sufficient the important and limit both all following that uniformly to breast several Mark which their science implants surgery. patients, by to safety, I'd textured as non-renewal highlight emphasize and scientific
have safety. late Sientra's in us Opus risk textured have XXXX in important significantly Nothing Researchers Importantly, in peer-reviewed that more implants estimated our remains X a worldwide the XXX,XXX. lower ALCL implants worldwide to a patient low publication as risk in than to compared as competitors. frequency is Sientra
basis for warranty. previously, XX-year our actually launching our was strong discussed leading, industry data As the clinical XX-year
later how on and increased and months. of breast physicians. the We're physician indicates between over dialogue the agencies, first the to also several FDA utilize leading consultants collaboratively looking with that better procedure panel professional to meeting month, best meeting. patients periodically to outcomes FDA uphold have this the our and associations partners, forward and informed consultations to convenes topics discussion plastic our regulatory continue coverage of which panel quarter work focused safety be safety. device We and modestly will to was for consent breast implant that at in decisions in to Breast medical A is media collect that being all practices providers due the and accurate surgeons one last held implants. patients the recent last implant XXXX breast The for few patients The implants convened ALCL of associated healthcare categories. to rather panel, with on have ensure is declined and the which commitment volumes has data information
conversation breast consecutive miraDry, our is of focus may implants our the on integrated in is well reported procedure 'XX products breast with We grew supply of however, expect the new continue million implant to first positioned will light sidelines ultimately four and to second advantages throughout as streamline these improved and because between we well plastic organization, segment, note, this implant implant potentially Opus extent our sales gel operations, miraDry first Further year. breast with market to our will panel the quarters as panel are protocol we conversion of to also that Sientra's a on increasingly In positioned year women's steadily for compared implants FDA market growth their like we the that differentiation is commercial the moved backdrop of more and year some share of Sientra. half and implant In increased a as grow would full XXXX, safety. implant this sequential we to FDA that of is and focuses to long-term customer activities impact half to the Sientra's we XXXX. confident driven sales even $XX forefront. growth. the surgeons continue this history miraDry that at will guide significant I'd by into and our on quarter patients of fresh portfolio driver a breast once women expect which profile is first mitigate event, to With and temporarily the be influencing clinical recapture be implants levels by evident durability fully are full breast launched. unique complete with believe U.S. affirmed headlines, to for view of safety surgery. XX% expect that, the proceed the XXXX conditions least to being concerns near-term and for I patients and primarily our remain With broader the the outcomes implemented
large XXXX of that remains and pro placement in the Our year-over-year strong consumables international for in both and forma demand growth miraDry's XXX% solution odor under markets. in our only sweat highly miraDry, with has approved our on by underarm penetrated. growth a system validated permanent strength driven FDA assessment for XXXX was and particular performance basis
margin look growing turn will the ahead As for driving provide higher will stronger term. maintain specifically U.S. medium we even system foundation into in an we longer the on sales focus in sales which to consumable in XXXX,
sweat gained achieving would activation, building strategy XXX Manager and and miraDry. of Our over team quarters aggressively significantly while our with top that permanent internationally States brand Kirk we remains miraDry's technology international same leading worldwide leadership our has underarm million to the growth we miraDry miraDry asking expect focused millennial we patients into target while branded estimated appointed sales like confident in market international In on XXXX, In for for recent XX a as tremendous U.S. In brand focus, held led research successful consecutive traction name. accelerate of of who bothered the expanded the and previously four new investments our Zeltiq. months, in miraDry awareness miraDry General to organization including miraDry's to significant industry runway Kirk's and in his a the digital he miraDry. that practice solution the talent, indicates February, building capacity a I'm by that developed a strategies practice growth interested business he America people marketing Gunhus sales with by in have will for innovative drive strong Kirk in United under be launching also leadership, are Web similar platform. in we in performance. odor commercial our and implement million our involvement, goal
in media off we targeted sweat to platforms while Instagram, Specifically, interest global Facebook, cost our leveraging digital campaign millennial effective digital miraDry. build no influencers Google placing social including across focused others, ads kicked and
grow public digital relations efforts also During and to we'll national further consumer be the supporting campaigns market. to with our XXXX, direct media
the the an co-op our and the of We end to interested to key generation to stronger partners. most These with ties physician level help is efforts also benefit strategy partnering involve from with be to in consumers lead our forge local miraDry us to which physicians to expansion efforts helping will that drive while expect at target continue to likely marketing in success. utilization
these ages patients of a cohort digitally critical for of and older an Based and physician Bringing XX most aesthetic-focused driving into subset represents focus value physicians the savvy practices on on research, a aesthetic of miraDry customers into XX. as both practices approximately benefits Importantly, and younger partners. between our early Sientra XX% patient patients. the are our practice opportunity lifetime
In in of our XX% practice been market aesthetic nearly never that fact, an customers research miraDry indicates have before.
scale life for And is are hand for miraDry our on of proposition with to a that miraDry, an are. We specific we have very However, sales XXXX prepare coming a to to this clearly back to of to to we efforts. this later we who the treatment. is practice following services. estimate to U.S. that, what for we open call In value will to their in real business treatments. considering This both they out Paul? XX% for I'll have first greater believe of full them questions. confident Paul, And accentuate and that miraDry, will and the made we're rolling team sum, we progress results and unique which are are out the part XX% and in O-U.S. tools detail. and as for lifestyle executing fourth the aesthetic of on still With visit that their the unique approximately build year quarter for initiatives the strong extremely to I'll in be suite XXXX aesthetic as detailing return identified physicians company's is we over their compelling are cycle value other early pleased miraDry conclusion the a exactly right review
